^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hepacid (pegargiminase)

    i
    Company:
    Polaris Pharma
    Drug class:
    Arginine depleter
    Apply
    ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers (NCT05616624)
    Phase 1/2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    04/05/2023
    Primary completion :
    12/31/2027
    Completion :
    12/31/2032
    EGFR • ALK • ROS1
    |
    EGFR mutation
    |
    gemcitabine • docetaxel • Hepacid (pegargiminase)
    Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (NCT06085729)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/01/2024
    Initiation :
    02/29/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2027
    TP53 • PTEN • RB1
    |
    TP53 mutation • PTEN mutation • LDH elevation
    |
    carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)
    Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma (NCT03922880)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    01/26/2023
    Initiation :
    04/16/2019
    Primary completion :
    01/20/2023
    Completion :
    01/20/2023
    GNAQ • GNA11 • CYSLTR2 • PLCB4
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Hepacid (pegargiminase)
    Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (NCT03498222)
    Phase 1
    Queen Mary University of London
    Withdrawn
    Last update posted :
    02/25/2020
    Initiation :
    06/01/2018
    Primary completion :
    01/31/2020
    Completion :
    12/31/2021
    EGFR
    |
    EGFR mutation • ALK positive
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • Hepacid (pegargiminase)
    Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer (NCT01948843)
    Phase 1
    Polaris Group
    Completed
    Last update posted :
    04/14/2016
    Initiation :
    04/01/2014
    Primary completion :
    04/01/2016
    Completion :
    04/01/2016
    HER-2
    |
    HER-2 negative
    |
    doxorubicin hydrochloride • Hepacid (pegargiminase)